Welcome to our dedicated page for Sandoz Group news (Ticker: SDZNY), a resource for investors and traders seeking the latest updates and insights on Sandoz Group stock.
Sandoz Group AG (SDZNY) generates frequent news flow as a global player in generic and biosimilar medicines. Company announcements cover product launches, clinical and pipeline updates, manufacturing investments, sustainability initiatives and corporate developments. Investors and healthcare observers following Sandoz news can see how the company’s generics and biosimilars strategy evolves across key therapeutic areas and geographies.
Recent news has highlighted US launches of denosumab biosimilars WYOST and Jubbonti, described as the first and only FDA‑approved interchangeable denosumab biosimilars available in the US, and the introduction of a generic iron sucrose injection for iron deficiency anemia in patients with chronic kidney disease. In Europe, Sandoz has reported the launch of the Pyzchiva (ustekinumab) autoinjector, the first ustekinumab biosimilar in Europe commercially available in a pre‑filled pen, aimed at improving self‑administration for patients with chronic inflammatory diseases.
News items also cover strategic manufacturing and sustainability moves, such as breaking ground on a new biosimilars production center in Brnik, Slovenia, and a 10‑year virtual power purchase agreement with Elawan Energy for solar projects in Spain, expected to meet nearly 90% of Sandoz electricity demand for European operations. Financial updates, including quarterly and half‑year net‑sales reports and guidance confirmations, provide insight into performance trends across generics and biosimilars and by region.
Visitors to the Sandoz news page on Stock Titan can review these developments over time, track new collaborations and potential acquisitions, and monitor how regulatory and legal milestones—such as biosimilar development decisions or competition‑related litigation—may influence the company’s trajectory.
Summary not available.
Summary not available.
Summary not available.
Summary not available.